Andrew Cheng - Jan 10, 2022 Form 4/A - Amendment Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President & CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Jan 10, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 3/2/2022, 08:42 PM
Date Of Original Report: Jan 11, 2022
Previous filing: Jan 4, 2022
Next filing: Feb 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKRO	Common Stock						309K	Jan 10, 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

This amendment is being filed to correct Andrew Cheng's aggregate beneficial holdings, which inadvertently excluded 10,000 shares of common stock held by Andrew Cheng prior to the exercise of his options in the reported transaction.